SCHEMBL5873284

SCHEMBL5873284

[c]1c(-c2ccc(-c3ccccc3)cc2)cc(-c2ccccc2)cc1-c1ccc(-c2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.42
TAAR1 Q96RJ0 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
MMP3 P08254 1/20 0.42
BCL2L1 Q07817 1/20 0.42
ALOX5 P09917 1/20 0.41
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
KDM4E B2RXH2 2/20 0.38
HTT P42858 2/20 0.38
NPC1 O15118 1/20 0.38
NTSR1 P30989 1/20 0.38
RAB9A P51151 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
UHRF1 Q96T88 1/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL456946 0.97 ALDH1A1 (0.50) ALDH1A1MAPK1TAAR1HSD17B10CYP1A2
SCHEMBL4647857 0.89 NPC1 (0.49) ALDH1A1TDP1ALOX5KDM4ENPC1
SCHEMBL723026 0.84 ALDH1A1 (0.40) ALDH1A1MAPK1TAAR1HSD17B10CYP1A2
SCHEMBL5873304 0.84 KIF11 (0.44) ALOX5KIF11DHODH
SCHEMBL28235453 0.81 CRHBP (0.43) ALDH1A1HSD17B10CYP1A2MMP3BCL2L1
SCHEMBL14635117 0.81 ALDH1A1 (0.39) ALDH1A1MAPK1CRHBPCRHR2KDM4E
SCHEMBL7950746 0.81 ALDH1A1 (0.35) ALDH1A1MAPK1CRHBPCRHR2KDM4E
SCHEMBL6761031 0.80 MEN1 (0.46) ALDH1A1MAPK1TAAR1HSD17B10CYP1A2
SCHEMBL3819329 0.78 RXRA (0.42) ALDH1A1TAAR1HSD17B10CYP1A2CYP3A4
SCHEMBL3822038 0.77 ALDH1A1 (0.38) ALDH1A1TAAR1CYP1A2TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056996-B2 Productivity catalysts and microstructure control E. I. DU PONT DE NEMOURS AND COMPANY (US) 2006-06-06 US disclosed
US-20040127658-A1 Productivity catalysts and microstructure control EASTMAN CHEMICAL COMPANY 2004-07-01 US disclosed
US-20040077809-A1 Productivity catalysts and microstructure control EASTMAN CHEMICAL COMPANY 2004-04-22 US disclosed
EP-1404723-A2 OLEFIN POLYMERIZATION PROCESSES USING SUPPORTED CATALYSTS EASTMAN CHEMICAL COMPANY (US) 2004-04-07 EP disclosed
EP-1351997-A2 IMPROVED PRODUCTIVITY CATALYSTS AND MICROSTRUCTURE CONTROL EASTMAN CHEMICAL COMPANY (US) 2003-10-15 EP disclosed
US-6605677-B2 Group 8-10 transition metal based supported catalyst where the support is treated with a pore-filling agent; improved the catalyst productivity in the presence of hydrogen EASTMAN CHEMICAL COMPANY 2003-08-12 US disclosed
US-20020091210-A1 Olefin polymerization processes using supported catalysts E. I. DU PONT DE NEMOURS AND COMPANY 2002-07-11 US disclosed
US-20020065192-A1 Productivity catalysts and microstructure control MACKENZIE PETER BORDEN (US) 2002-05-30 US disclosed
WO-2002036641-A2 IMPROVED PRODUCTIVITY CATALYSTS AND MICROSTRUCTURE CONTROL EASTMAN CHEMICAL COMPANY (US) 2002-05-10 WO disclosed
WO-2002036642-A2 OLEFIN POLYMERIZATION PROCESSES USING SUPPORTED CATALYSTS EASTMAN CHEMICAL COMPANY (US) 2002-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077809-A1 Productivity catalysts and microstructure control MYB, ST3GAL3, FASN ALDH1A1 3431/4885MAPK1 2128/4885TAAR1 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.